tiprankstipranks
Definium Therapeutics (DFTX)
NASDAQ:DFTX
US Market
DFTX
Definium Therapeutics
RESEARCH TOOLSreports
Want to see DFTX full AI Analyst Report?

Definium Therapeutics (DFTX) Stock Forecast & Price Target

2,449 Followers
See the Price Targets and Ratings of:

DFTX Analyst Ratings

Strong Buy
15Ratings
Strong Buy
15 Buy
0 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Definium
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DFTX Stock 12 Month Forecast

Average Price Target

$69.13
▲(54.28% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Definium Therapeutics in the last 3 months. The average price target is $69.13 with a high forecast of $91.00 and a low forecast of $53.00. The average price target represents a 54.28% change from the last price of $44.81.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","29":"$29","50":"$50","71":"$71","92":"$92"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$91.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.13333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$69.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$53.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,29,50,71,92],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.5,42.53846153846154,46.57692307692308,50.61538461538461,54.65384615384615,58.69230769230769,62.730769230769226,66.76923076923077,70.8076923076923,74.84615384615384,78.88461538461539,82.92307692307692,86.96153846153845,{"y":91,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.5,40.85641025641026,43.212820512820514,45.56923076923077,47.92564102564103,50.282051282051285,52.63846153846154,54.9948717948718,57.351282051282055,59.70769230769231,62.06410256410257,64.42051282051283,66.77692307692308,{"y":69.13333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.5,39.61538461538461,40.73076923076923,41.84615384615385,42.96153846153846,44.07692307692308,45.19230769230769,46.30769230769231,47.42307692307692,48.53846153846154,49.65384615384615,50.769230769230774,51.88461538461539,{"y":53,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.23,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.18,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.06,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.52,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.5,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$91.00Average Price Target$69.13Lowest Price Target$53.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DFTX
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$70
Buy
56.22%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Innovent Biologics (Other OTC: IVBXF) and Definium Therapeutics (NASDAQ: DFTX)
Needham Analyst forecast on DFTX
Ami Fadia
Needham
Needham
$66
Buy
47.29%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: AxoGen (NASDAQ: AXGN) and Definium Therapeutics (NASDAQ: DFTX)
Oppenheimer Analyst forecast on DFTX
Jay Olson
Oppenheimer
Oppenheimer
$70→$75
Buy
67.37%
Upside
Reiterated
09/14/26
Definium Therapeutics price target raised to $75 from $70 at OppenheimerDefinium Therapeutics price target raised to $75 from $70 at Oppenheimer
Bank of America Securities Analyst forecast on DFTX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$75→$91
Buy
103.08%
Upside
Reiterated
09/14/26
Definium Therapeutics price target raised to $91 from $75 at BofADefinium Therapeutics price target raised to $91 from $75 at BofA
LifeSci Capital Analyst forecast on DFTX
Francois Brisebois
LifeSci Capital
LifeSci Capital
$75→$78
Buy
74.07%
Upside
Reiterated
09/14/26
Analysts' Top Healthcare Picks: Corbus Pharmaceuticals (CRBP), Definium Therapeutics (DFTX)
RBC Capital Analyst forecast on DFTX
Brian Abrahams
RBC Capital
RBC Capital
$66
Buy
47.29%
Upside
Reiterated
09/11/26
Analysts' Top Healthcare Picks: Adagene (ADAG), AbbVie (ABBV)
Canaccord Genuity Analyst forecast on DFTX
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$64
Buy
42.83%
Upside
Reiterated
09/02/26
Analysts Offer Insights on Healthcare Companies: Enovis (NYSE: ENOV), Adicet Bio (NASDAQ: ACET) and Definium Therapeutics (NASDAQ: DFTX)
Stifel Nicolaus Analyst forecast on DFTX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$60
Buy
33.90%
Upside
Reiterated
08/31/26
Definium Therapeutics (DFTX) Gets a Buy from Stifel Nicolaus
Wells Fargo Analyst forecast on DFTX
Benjamin Burnett
Wells Fargo
Wells Fargo
$72
Buy
60.68%
Upside
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (NASDAQ: VOR), Definium Therapeutics (NASDAQ: DFTX) and IDEAYA Biosciences (NASDAQ: IDYA)
Piper Sandler Analyst forecast on DFTX
David Amsellem
Piper Sandler
Piper Sandler
$75
Buy
67.37%
Upside
Reiterated
08/17/26
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Immuneering (IMRX)
Jefferies Analyst forecast on DFTX
Andrew Tsai
Jefferies
Jefferies
$65
Buy
45.06%
Upside
Reiterated
08/13/26
Analysts' Top Healthcare Picks: MaxCyte (MXCT), Definium Therapeutics (DFTX)
JonesTrading Analyst forecast on DFTX
Justin Walsh
JonesTrading
JonesTrading
$74→$90
Buy
100.85%
Upside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Olympus (Other OTC: OCPNF), Journey Medical Corp (NASDAQ: DERM) and Definium Therapeutics (NASDAQ: DFTX)
Maxim Group Analyst forecast on DFTX
Michael Okunewitch
Maxim Group
Maxim Group
$50→$55
Buy
22.74%
Upside
Assigned
08/13/26
Analysts Conflicted on These Healthcare Names: Definium Therapeutics (NASDAQ: DFTX), Ionis Pharmaceuticals (NASDAQ: IONS) and Sutro Biopharma (NASDAQ: STRO)
Evercore ISI Analyst forecast on DFTX
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$53
Buy
18.28%
Upside
Reiterated
08/10/26
Evercore ISI Sticks to Its Buy Rating for Definium Therapeutics (DFTX)
Robert W. Baird Analyst forecast on DFTX
Christopher Chen
Robert W. Baird
Robert W. Baird
$37→$57
Buy
27.20%
Upside
Reiterated
06/23/26
Definium Therapeutics price target raised to $57 from $37 at BairdDefinium Therapeutics price target raised to $57 from $37 at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DFTX
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$70
Buy
56.22%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Innovent Biologics (Other OTC: IVBXF) and Definium Therapeutics (NASDAQ: DFTX)
Needham Analyst forecast on DFTX
Ami Fadia
Needham
Needham
$66
Buy
47.29%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: AxoGen (NASDAQ: AXGN) and Definium Therapeutics (NASDAQ: DFTX)
Oppenheimer Analyst forecast on DFTX
Jay Olson
Oppenheimer
Oppenheimer
$70→$75
Buy
67.37%
Upside
Reiterated
09/14/26
Definium Therapeutics price target raised to $75 from $70 at OppenheimerDefinium Therapeutics price target raised to $75 from $70 at Oppenheimer
Bank of America Securities Analyst forecast on DFTX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$75→$91
Buy
103.08%
Upside
Reiterated
09/14/26
Definium Therapeutics price target raised to $91 from $75 at BofADefinium Therapeutics price target raised to $91 from $75 at BofA
LifeSci Capital Analyst forecast on DFTX
Francois Brisebois
LifeSci Capital
LifeSci Capital
$75→$78
Buy
74.07%
Upside
Reiterated
09/14/26
Analysts' Top Healthcare Picks: Corbus Pharmaceuticals (CRBP), Definium Therapeutics (DFTX)
RBC Capital Analyst forecast on DFTX
Brian Abrahams
RBC Capital
RBC Capital
$66
Buy
47.29%
Upside
Reiterated
09/11/26
Analysts' Top Healthcare Picks: Adagene (ADAG), AbbVie (ABBV)
Canaccord Genuity Analyst forecast on DFTX
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$64
Buy
42.83%
Upside
Reiterated
09/02/26
Analysts Offer Insights on Healthcare Companies: Enovis (NYSE: ENOV), Adicet Bio (NASDAQ: ACET) and Definium Therapeutics (NASDAQ: DFTX)
Stifel Nicolaus Analyst forecast on DFTX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$60
Buy
33.90%
Upside
Reiterated
08/31/26
Definium Therapeutics (DFTX) Gets a Buy from Stifel Nicolaus
Wells Fargo Analyst forecast on DFTX
Benjamin Burnett
Wells Fargo
Wells Fargo
$72
Buy
60.68%
Upside
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (NASDAQ: VOR), Definium Therapeutics (NASDAQ: DFTX) and IDEAYA Biosciences (NASDAQ: IDYA)
Piper Sandler Analyst forecast on DFTX
David Amsellem
Piper Sandler
Piper Sandler
$75
Buy
67.37%
Upside
Reiterated
08/17/26
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Immuneering (IMRX)
Jefferies Analyst forecast on DFTX
Andrew Tsai
Jefferies
Jefferies
$65
Buy
45.06%
Upside
Reiterated
08/13/26
Analysts' Top Healthcare Picks: MaxCyte (MXCT), Definium Therapeutics (DFTX)
JonesTrading Analyst forecast on DFTX
Justin Walsh
JonesTrading
JonesTrading
$74→$90
Buy
100.85%
Upside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Olympus (Other OTC: OCPNF), Journey Medical Corp (NASDAQ: DERM) and Definium Therapeutics (NASDAQ: DFTX)
Maxim Group Analyst forecast on DFTX
Michael Okunewitch
Maxim Group
Maxim Group
$50→$55
Buy
22.74%
Upside
Assigned
08/13/26
Analysts Conflicted on These Healthcare Names: Definium Therapeutics (NASDAQ: DFTX), Ionis Pharmaceuticals (NASDAQ: IONS) and Sutro Biopharma (NASDAQ: STRO)
Evercore ISI Analyst forecast on DFTX
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$53
Buy
18.28%
Upside
Reiterated
08/10/26
Evercore ISI Sticks to Its Buy Rating for Definium Therapeutics (DFTX)
Robert W. Baird Analyst forecast on DFTX
Christopher Chen
Robert W. Baird
Robert W. Baird
$37→$57
Buy
27.20%
Upside
Reiterated
06/23/26
Definium Therapeutics price target raised to $57 from $37 at BairdDefinium Therapeutics price target raised to $57 from $37 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
JAZZJazz Pharmaceuticals
ONCBeOne Medicines
VKTXViking Therapeutics
HROWHarrow Health
KURAKura Oncology
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Definium Therapeutics

3 Months
Sumant KulkarniCanaccord Genuity
Success Rate
11/15 ratings generated profit
73%
Average Return
+34.62%
Copying Sumant Kulkarni's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +34.62% per trade.
1 Year
Patrick TrucchioH.C. Wainwright
Success Rate
15/17 ratings generated profit
88%
Average Return
+127.25%
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +127.25% per trade.
2 Years
Patrick TrucchioH.C. Wainwright
Success Rate
16/17 ratings generated profit
94%
Average Return
+264.77%
Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +264.77% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DFTX Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
31
36
22
23
22
Buy
4
11
9
20
13
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
47
31
43
35
In the current month, DFTX has received 35 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DFTX average Analyst price target in the past 3 months is 69.13.
Each month's total comprises the sum of three months' worth of ratings.

DFTX Financial Forecast

DFTX Earnings Forecast

Next quarter’s earnings estimate for DFTX is -$0.56 with a range of -$0.70 to -$0.45. The previous quarter’s EPS was -$1.44. DFTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DFTX has Performed in-line its overall industry.
Next quarter’s earnings estimate for DFTX is -$0.56 with a range of -$0.70 to -$0.45. The previous quarter’s EPS was -$1.44. DFTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DFTX has Performed in-line its overall industry.
No data currently available

DFTX Sales Forecast

Next quarter’s sales forecast for DFTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DFTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DFTX has Performed in-line its overall industry.
Next quarter’s sales forecast for DFTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DFTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DFTX has Performed in-line its overall industry.

DFTX Stock Forecast FAQ

What is DFTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Definium Therapeutics’s 12-month average price target is 69.13.
    What is DFTX’s upside potential, based on the analysts’ average price target?
    Definium Therapeutics has 54.28% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DFTX a Buy, Sell or Hold?
          Definium Therapeutics has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Definium Therapeutics’s price target?
            The average price target for Definium Therapeutics is 69.13. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $91.00 ,the lowest forecast is $53.00. The average price target represents 54.28% Increase from the current price of $44.81.
              What do analysts say about Definium Therapeutics?
              Definium Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of DFTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.